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Introduction
A successful extrachromosomal, or episome-based, somatic gene therapy system for inherited genetic disorders has to fulfill at least three basic requirements. First, the vector would have to persist for prolonged periods in the nucleus of the cell without integrating into the host's genome. Ideally, a single or multicopy plasmid whose replication could be efficiently regulated to only once per cell cycle should be utilized. Integration of a therapeutic episome into the host's chromatin is undesirable for several main reasons: integration could inactivate any gene residing on the vector; integration has a distinct possibility of activating or inactivating important genetic loci potentially resulting in deleterious consequences. Second, the newly replicated plasmid(s) would have to segregate to daughter cell nuclei efficiently, ensuring a steady-state copy number of the plasmid. Efficient episomal maintenance (replication and segregation) would ensure that the therapeutic vector persists in the treated cells for the entire life of the individual. Finally, the vector would deliver sustained expression of the therapeutic gene for prolonged periods, avoiding repressive mechanisms of gene regulation such as chromatin condensation and methylation at CpG sites in promoters.
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Received 2 October 1997; accepted 14 May 1998 The Epstein-Barr virus (EBV) presents itself as a useful viral system potentially to meet the above criteria as an episomal gene delivery vector. EBV is a large 172-kb double-stranded DNA herpesvirus that preferentially infects B lymphocytes, although it has been detected in a variety of other tissues as well. [1] [2] [3] Once the linear viral DNA enters the cell it recircularizes and subsequently establishes a latent pattern of replication in the nucleus of the infected cell for the life of the individual. The viral genome is then replicated only once per cell division cycle [4] [5] [6] by the host's DNA replication machinery in synchrony with the host's genome. The large viral episome has been found to maintain a stable copy number of between five and 50 per cell nucleus in Burkitt's lymphoma (BL) and lymphoblastoid cell lines (LCL).
Small helper-dependent miniEBV plasmids hvae been developed which carry the latent origin of replication of EBV (oriP) and other cis-DNA elements required for producing an infectious amplicon virus capable of establishing latency in infected cells (for review see Ref. 7) . Derivatives of this miniEBV have been successfully used to transport and express several recombinant genes in B lymphocytes. [8] [9] [10] Latent replication of the EBV genome depends on only one viral encoded DNA binding protein referred to as Epstein-Barr nuclear antigen 1 (EBNA1). This antigen has no detectable intrinsic enzymatic activity but binds to multiple locations in the EBV genome, specifically at the origin of bidirectional replication (OBR or dyad sym-metry element, DS) and at a cluster of 20 consecutive binding sites called the family of repeats (FR). These two cis elements, together referred to as oriP, are separated by approximately 1000 bp of nonessential DNA and function in latent DNA replication, plasmid maintenance and transcriptional enhancement, all of which depend upon the binding of EBNA1 protein. 11 Stable maintenance of oriP-containing plasmids in dividing cells involves two EBNA1-dependent functions: the initiation of plasmid replication at the OBR; [12] [13] [14] and a replication-independent plasmid maintenance function. EBNA1 dimers bound to oriP physically link FR to the OBR (DS), resulting in the formation of a loop consisting of the intervening DNA separating these two elements. [15] [16] [17] This linking activity is required for the three activities of oriP mentioned above. 11 The EBNA1 protein has been extensively studied through detailed mutational analysis and several functional domains of EBNA1 have been mapped ( Figure 1 ). [18] [19] [20] [21] [22] [23] Although the nuclear localization signal (NLS), the DNA binding and dimerization domain, and the DNA linking (or looping) domains have been mapped, a consensus transcriptional activation domain has not yet been discovered. The amino terminal onethird of EBNA1 contains a large, variable repeat region with a high GlycylAlanine content, referred to either as internal repeat 3 (IR3) or GlyAla domain. 24 Although it has been reported that deletion of a large segment of this domain has no profound affect on the function of EBNA1 in transient experiments, 18, 24 it has been shown to interfere with antigen processing and/or presentation of EBNA1 to the cellular immune compartment. 25, 26 Interestingly, it has also been shown that this immune escape function can be transmitted to other proteins when fused to this domain. 26 Several lines of evidence indicate a potential effect of the GlyAla repeat on EBNA1 function. Short-term DNA transfection experiments comparing mutant and wildtype EBNA1 proteins on reporter constructs revealed a subtle effect on episomal replication, reporter gene transactivation and plasmid copy number. 18 In long-term cell transformation experiments, we have observed a differential stability of transduced the pH210 vector ( Figure 2 ) in different EBV-positive human B cell lines latently infected with different strains of EBV. Specifically, it was observed that the B lymphoma Raji cell line was able to maintain oriP-based reporter expression more efficiently than the B lymphoblastoid cell line HSC536. 8 Recent experiments from our laboratory with stably transduced pH210 vector in additional EBV-positive Burkitt's lymphoma lines further support a correlation between the isoform of EBNA1 being expressed and long-term stability of oriP-based plasmids (Wendelburg, Banerjee and Vos, in preparation). Although such an effect could be due to genetic differences between these cell lines, it could also be a function of the EBNA1s being expressed by different strains of EBV resident in these cells. As the molecular weight of EBNA1 can vary due to length variations in the GlyAla domain, we were interested in determining whether this unusual structure may contribute to stability of oriP/EBNA1 episomes. HSC536 cells harbor the B95.8 strain of EBV and express an EBNA1 of approximately 76 kDa, with approximately 268 amino acids composing the GlyAla domain. The Raji strain of EBV expresses an EBNA1 with a molecular weight of 67 kDa due to a reduction in the GlyAla domain to approximately 170 amino acids (see below).
To investigate this further we isolated the EBNA1 gene from the resident EBV in the nonproducer African Burkitt's lymphoma Raji using a novel cloning strategy. The result of a major truncation (224 amino acids) of this domain on EBNA1 activity was also examined. Here, we show in long-term gene transduction experiments that the GlyAla repeat encoded in the EBNA1 protein positively influences long-term maintenance of oriP-based plasmids in human B cells. These results could have important implications for the design and development of episomal gene delivery vectors which rely on efficient and optimal EBNA1 function to maintain themselves as episomal vectors in the host's cell nucleus.
Results

Cloning and functionality of various EBNA1 isoforms
Cloning of a novel EBNA1 from the EBV-positive non-producer strain Raji: Because Raji EBV cannot be produced from its' latently infected host cell, we derived an alternative cloning strategy based on selective alkaline extraction and purification of the latent 172 kb circular viral episome. High molecular weight extrachromosomal DNA was extracted from Raji by an alkaline lysis procedure. 10 As described in Materials and methods, the lysate containing large circular EBV episomes was double digested and shotgun ligated into vector pGEM3zf(+). Approximately 500 transformants were screened by colony hybridization and seven positive clones were identified. DNA was isolated from these seven clones and sequencing of the first 200 bp of unique sequence directly 3Ј to the internal repeat (IR3) domain confirmed that all EBNA1 clones were identical. The complete DNA sequence of one clone was determined (with the exception of the GlyAla domain) and compared with the standard B95.8-derived EBNA1 sequence. A comparison of the amino acid differences between several EBNA1 proteins is summarized in Figure 1 . As previously shown, 27 we determined by restriction analysis that the GlyAla repeat (IR3) of the Raji EBNA1 gene was approximately 300 bp shorter than that of the B95.8 (which is approximately 807 bp) EBNA1 gene. This is in accordance with the size difference between the two EBNA1 proteins (76 versus 67 kDa). 
Construction of oriP plasmids expressing different EBNA1 isoforms:
In order to test the expression and function of each EBNA1 protein, a series of oriP vectors were created using the same expression cassette that encodes different EBNA1 genes. To test the affect of the GlyAla domain on EBNA1 function the coding region of a truncated form of the B95.8 EBNA1 derived from plasmid pREP7 (Invitrogen) was included. The EBNA1 protein expressed from this gene is approximately 46 kDa since it encodes only a small portion of the original GlyAla domain (44 amino acids from an original 268). 24 The backbone of the plasmids used in these analyses is based on the parental vector pH211 depicted in Figure 2 . This oriP-based plasmid 8 also encodes an SV40 promoter-driven lacZ gene for assaying transgene expression. HindIII expression cassettes, derived from the plasmid pCMVEBNA1 (Invitrogen), were engineered encoding different isoforms of EBNA1 transcribed from the viral cytomegalovirus (CMV) immediate-early promoter ( Figure 2 ) and inserted into the HindIII site of pH211. The coding regions of the Raji and IR3del EBNA1 genes were swapped with the EBNA1 coding region of pCMVEBNA1 to create identical expression cassettes for these different isoforms.
Stable episomal transformation of human B cells with oriP plasmids encoding various EBNA1 isoforms: To determine the effect of GlyAla repeat length on different EBNA1 isoforms each oriP/EBNA1 expression construct was transfected into DG75 cells by electroporation. This EBV-negative Burkitt's lymphoma cell line was chosen because of its lack of endogenous EBNA1. 28 To minimize the effect of clonal differences in gene expression hygromycin-resistant cell pools were used throughout this study. Episomes were prepared from stably transformed pools at 5 weeks after transfection and analyzed by Southern blotting to determine the extrachromosomal status of the various plasmids. To enhance signal detection episomes were linearized with the single cutter BglII and resolved by agarose pulse field gel electrophoresis (PFGE). Southern analysis revealed that full-size, unrearranged 23 kb episomes were present in cells transfected with all three plasmids ( Figure 3a , lanes 1, 2 and 3). The BglII linearized plasmid pCMVB95.8.E1 was included in lane 4 as a molecular weight control. Thus, all three isoforms of EBNA1 appeared to support extrachromosomal plasmid maintenance.
Relative expression and sizes of different EBNA1 isoforms: The comparative expression levels and molecular weight of the EBNA1 isoforms were analyzed in the DG75 transformants by Western analysis using an EBNA1-specific monoclonal antibody. 21 Total protein was prepared and equal amounts were separated by SDSpolyacrylamide gel electrophoresis. As illustrated in Figure 3b (lanes 3, 4 and 5) the differences in molecular weight of the recombinant EBNA1 proteins predicted EBNA1 proteins were expressed at approximately twothirds and one-tenth, respectively, the level of the recombinant Raji EBNA1.
Expression of a transgene from stably transduced oriP episomes: Because sustained production of a transgene is the primary goal in gene delivery vectors, an ONPG colorimetric assay was used to determine the expression levels of the reporter ␤-galactosidase (lacZ) gene encoded on these plasmids ( Figure 2 ). As shown in Figure 3c , all three episomal plasmids expressing the various recombinant EBNA1 proteins were competent in expressing high levels of the lacZ gene compared with the amplicon pH210 vector in the Raji-positive control. The pH211 control vector with no EBNA1 gene produced little or no detectable lacZ activity, presumably a result of vector integration. These results indicate that cells with stably transduced extrachromosomal plasmids were capable of expressing high levels of reporter gene, while those with presumably integrated pH211 vectors did not, as assayed on pooled transformants. Identical transformation experiments (not shown) using EBNA1 expression cassettes driven from a weaker murine cellular PGK promoter were also unable to produce detectable lacZ activity. Even though episomes were no longer detectable in the transformants, the Hyg r gene must still be actively expressed since the cells remain sensitive to the selection medium. These experiments reveal that regardless of the size of the GlyAla repeat, episomal status can be achieved with subsequent high level transgenic expression.
Differential long-term functionality of EBNA1 isoforms
Long-term trans-gene expression from oriP episomes encoding different EBNA1 isoforms: An effective extrachromosomal gene therapy system requires that the vector be stably replicated and efficiently segregated from daughter cells for prolonged periods. To compare plasmid maintenance of the different oriP/EBNA1 containing vectors the transformed pools were grown continuously in the presence of the selection agent (hygromycin) for up to 6 months. Figure 4a shows a Southern analysis of episomes prepared from these cultures at 5 months after transfection. The B95.8 and the Raji EBNA1 expressing episomes were easily detectable at equivalent levels (lanes 1 and 2). However, there was complete loss of episomes expressing the truncated EBNA1 protein, CMVIR3del.E1 (lane 3). These results imply that truncated EBNA1 proteins are less efficient in long-term maintenance of oriP/EBNA1 plasmids than wild-type B95.8 or Raji EBNA1 isoforms. Since the only difference between the B95.8 EBNA1 and the IR3del EBNA1 is the size of the GlyAla repeat, this region must influence the stability of OriP/EBNA1 plasmids.
The EBNA1-specific Western analysis of the transformants revealed that EBNA1 protein expression was dramatically and differentially reduced in both B95.8.E1 and IR3del.E1 clones compared with Raji.E1 in 5 month cultures (Figure 4b, lanes 6 and 8) . For quantitative comparison, EBNA1 protein expressed in each transformant at 1 month was included in the analysis (lanes 1-3, Figure 4b ). Specifically, we were unable to detect EBNA1 protein expressed from the CMVIR3del.E1 construct (compare lane 8 with lane 3). Therefore, the lack of detectable EBNA1 protein in this transformant at 5 months (lane 8) correlated with their lack of episomes (Figure 4a, lane 3) . A significant reduction in the level of EBNA1 protein expressed from the CMVB95.8.E1 construct was also detected relative to the CMVRaji.E1 transformants (compare lanes 6 and 7 with lanes 1 and 2, respectively). The level of B95.8 EBNA1 protein expressed at 5 months in lane 6 was estimated to be approximately 10-15% of the Raji EBNA1 in lane 7, indicating a four-to six-fold relative reduction in expression compared with the 1 month time-point. Even though there appears to be an approximate 10-fold difference in the steady-state level of EBNA1 protein expressed between the CMVRaji.E1 and CMVB95.8.E1 transformants, there is less than a two-fold difference in plasmid copy number (see Figure 4a , compare lanes 1 and 2, see below).
The activity of the lacZ gene expressed from each of these constructs was assayed periodically over the course of 6 months. Results from the graphical analysis in Figure 4c indicate differential loss of lacZ activity which appears relatively consistent with episome copy numbers and the presence of EBNA1. After 5 months, the CMVB95.8.E1 and CMVRaji.E1 clones produced, respectively, 45 and 89% of the Raji pH210 control, while lacZ expression from CMVIR3del.E1 was almost undetectable (less than 3% of control).
In an effort to corroborate the above findings, two additional cell lines were transfected with the same oriP/EBNA1 constructs (CMVRaji.E1 and CMVIR3del.E1) prepared at different times. The cell lines were BJAB, an EBV-negative Burkitt's lymphoma cell line, and HH514, an EBV-positive lymphoblastoid cell line. After transfection (10 g DNA) stable cell pools were obtained by selection in antibiotic as above and the cells were then cultured for a total of 14 weeks (3.5 months). ONPG assays (Figure 4d ) on the BJAB and HH514 transformants revealed that lacZ activity from the two CMVEBNA1 constructs differentially declined from initial equivalent levels. After 3.5 months the lacZ activity determined for the GlyAla deletion mutant in BJAB and HH514 cells was only 20 and 2.9%, respectively, the level of the level determined in the CMVRaji.E1 transformants. These results mirror and thus support the data seen with the DG75 transformants.
Differential kinetics of episomal persistence: To improve quantification of the extrachromosomal persistence of episomes as a function of time an internal control was included in the long-term experiments. Since the amount of mitochondrial DNA in a cell line is expected to be stable over time in culture it can provide an adequate extrachromosomal internal control for measuring copy number of co-extracted recombinant episomes. The relative amounts of OriP/EBNA1 plasmids was normalized to the amount of co-extracted mitochondrial genomes. To estimate the copy number per cell of the extracted episomes 100 pg of HindIII-digested pCMVB95.8.E1 DNA was also included in the analysis. Figure 5a shows a typical Southern analysis illustrating this normalization assay. Episomes prepared at 1 month intervals over 6 months were linearized and resolved by PFGE as above. 
-gal activities were plotted on the y-axis (-b-, CMVB958.E1; -᭺--, CMVRaji.E1; ---२---, CMVIR3del.E1). (d) Differential loss of lacZ gene activity in BJAB and HH514 cells. CMVRaji.E1 and CMVIR3del.E1 expression plasmids were transfected (10 g) into BJAB and HH514 cells. Hygromycin-resistant pools were grown continuously for 3.5 months in culture. LacZ gene activity was measured (OD at 420 nm) at 1 month and 3.5 months after transfection. The lacZ gene activity of each transformant was normalized to the CMVRaji.E1 value of each cell line and reported as per cent of CMVRaji lacZ expression. Each DNA clone and cell line is indicated below the histograms.
faint band just below the vector fragment is a nonspecific signal arising from the huMit probe, as seen in the DG75-negative control (lane 20). Lane 1 confirmed the absence of episomal plasmid in DG75 cells transformed by the parental pH211 without EBNA-1. Each triplicate set of lanes represents episomes extracted from CMVB95.8.E1, CMVRaji.E1, CMVIR3del.E1 transformants, respectively, at 1 month time intervals up to 6 months.
Graphical analysis of episome copy number determination over the 6-month interval (Figure 5b ) revealed a kinetic difference between the wild-type EBNA1s and the mutant protein. Surprisingly, the results of this experiment showed that the initial copy number of the CMVB95.8.E1 plasmid was approximately 2.5 per cell in the first month after transfection (lane 2, Figure 5a ), but increased more than five-fold by the third month to 16 episomes per cell (lane 8). Subsequently, the copy number began to decline such that by month 6 the episomes were undetectable in lane 17. The initial copy number of the CMVRaji.E1 expression construct at 1 month was almost 20 per cell (lane 3), and increased to its maximum value of approximately 24 per cell in the second month (lane 6). Thereafter, the copy number began to decline such that by month 6 it was less than 10% of its maximum value (approximately two per cell, lane 18). The CMVIR3del.E1 expression plasmid only reached a maximum copy number of four per cell in the first month (lane 4), was stable until month 3 and became undetectable by month 4 (lane 13). Because the underlying difference between the B95.8 and the IR3del EBNA1 clone is length of the GlyAla repeat, the results demonstrate that this unusual structure in the EBNA1 protein influences long-term stability of oriP-based plasmids in stable B cell transformants.
Figure 5 (a) Long-term quantitative Southern analysis of oriP episomes. Transformed cells were grown continuously for up to 6 months after transfection. Episomal extracts were prepared from the pooled transformants at 1 month time intervals, linearized with HindIII and resolved by PFGE. The blot was co-hybridized with 32 P-labeled probes specific for the episomal oriP plasmids (EBNA1 gene) and human mitochondrial (huMit) DNA. Time intervals are indicated under the figure. Starting at lane 2, each group of three lanes represents samples derived from CMVB95.8.E1, CMVRaji.E1 and CMVIR3del.E1 transformants every month over 6 months, respectively. The top band is the signal derived from the 20.3-kb pH211 backbone of the expression cassettes; the bottom band is the signal derived from the 5.0-kb HindIII fragment of huMit DNA. The faint signal just below the pH211 band is nonspecific for the huMit probe. Lane 1 is pH211 (EBNA1-negative) transfected DG75 as non-episomal control. Lane 20 is untransfected parental DG75. Lane 21 is 100 pg of linearized pCMVB95.8 DNA as episomal copy number standard. (b) Graphical analysis of quantitative loss of episomal oriP/EBNA1 plasmids in long-term cultures. From Figure 5a, the signal from each oriP plasmid in each time interval was normalized to the signal from its huMit internal standard. The plasmid copy number of each transformant was then estimated from the intensity of the signal from the copy number control plasmid LpH211 in lane 21 of Figure 5a. The plasmid copy number in each time-point is plotted in graphical form on a semilog scale to show the differential loss of the different EBNA1 expressing plasmids. Timepoints in months are plotted on the x-axis and the copy number are plotted on the y-axis (-b-, CMVB958.E1; -᭺--, CMVRaji.E1; ---२---, CMVIR3del.E1).
Discussion
This study reveals a novel influence of the GlyAla repeat (IR3) of EBNA1 which affects oriP/EBNA1 plasmid stability and ensuing transgene expression. It was shown that the absence of this domain reduced plasmid persistence in long-term assays of stably transformed human B lymphoid cells. Different isoforms of the EBNA1 protein containing differing amounts of this structure were examined for their ability to maintain OriP/EBNA1 plasmids for up to 6 months in tissue culture. The EBNA1 protein of the B95.8 strain of EBV was examined, as well as a GlyAla domain deletion mutant originally derived from the B95.8 EBNA1 gene. 23 The GlyAla domain of this EBNA1 is reduced by approximately 224 amino acids (from an original 268 amino acids). A novel, functional EBNA1 from the nonproducer African Burkitt's lymphoma Raji, was cloned and included in the examination. In addition to a total of 15 single amino acid differences in the EBNA1 coding region, the Raji EBNA1 gene encodes a GlyAla domain that is approximately 170 amino acids in length, or 100 amino acids shorter than the B95.8 EBNA1 protein. A series of EBNA1 expression cassettes driven by the strong CMV promoter was constructed. To avoid endogenous EBNA1 activity EBV-negative B cells were used in these experiments and pooled stable transformants were used to eliminate any clonal differences in gene expression.
We have previously observed that pH210-based transgene expression persisted at a higher level in transduced EBV-positive Raji Burkitt's lymphoma cells than in EBVpositive HSC536 lymphoblastoid cells. 8 Over the course of 3 months without selection, we determined that there was a differential rate of loss in episome copy number of 75 and 33% in Raji and HSC536 cells, respectively (unpublished data). Plasmid retention depends on the efficiency of replication and segregation of plasmids from daughter cells. The difference in plasmid stability between these two cell lines may be a reflection of inherent metabolic differences between the cancer B cell line Raji and the in vitro transformed lymphoblastoid line HSC536 derived from a Fanconi's anemia patient. 8 Alternatively, since Raji and HSC536 cells express different isoforms of EBNA1 protein, this could reflect differences in their ability to interact with the OriP element. Yates and Camiolo 18 observed in short-term transfection experiments that the GlyAla deletion mutant DL7 (identical to the IR3del clone used in our experiments) was able to stimulate (two-fold) replication of oriP-based plasmids modestly, enhance transcription (two-fold) of FR-containing reporter constructs and allow a higher plasmid copy number (two-fold) per cell as compared with the wildtype control B95.8 EBNA1. These observations suggested a subtle transient effect that the GlyAla domain may impart to the activity of the EBNA1 protein. In contrast, we observed that the lack of the GlyAla domain negatively influenced EBNA1 function, ie promoted plasmid loss. In these long-term experiments (up to 6 months after transformation), a 10-to 100-fold reduction in episomal plasmid and ␤-gal activity was observed over time. Several reasons may explain these different results. First, Yates and Camiolo used the human osteosarcoma 143 line, while our study relies on human B cell lines, the natural site of residence of the latent EBV. The activity of the OriP/EBNA-1 system may be differentially affected by tissue-specific factors. Second, the negative effect of the IR3-deleted EBNA-1 only became apparent after at least 3 months of cell culture (Figures 4c and 5b) . Since the previous experiments 18 did not extend beyond approximately 1 month, a small reduction in a specific EBNA-1 activity may only be manifested through a longterm experiment. Lastly, transcriptional activation and episomal replication by EBNA-1 on OriP may be stimulated by the IR3 deletion, while episomal segregation cru-cial for long-term maintenance may be selectively inhibited. If so, the IR3-deleted derivative would be a segregation-specific mutant.
Differential long-term functionality of various transactivating EBNA1 isoforms
The long-term plasmid maintenance assay of Figure 5a revealed striking differences in the functional activity of different isoforms of EBNA1. The graphical analysis of these results, shown in Figure 5b , implies differential kinetics for each EBNA1 isoform. Specifically, the relative copy number of the Raji, B95.8 and GlyAla mutant (CMVIR3del.E1) EBNA1-expressing plasmids reached different maximum levels at different time intervals after transfection and stable selection. The plasmid encoding the GlyAla mutant (CMVIR3del.E1) attained a maximum copy number of only four per cell in the first month (20% of the CMVRaji plasmids). The copy number in these transformants remained relatively stable until the third month after transfection, and were undetectable by the fourth month. In contrast, the maximum copy number of the CMVRaji.E1 plasmids reached about 24 per cell 2 months after transfection, while the CMVB95.8.E1 plasmids peaked at about 16 per cell, and not until the third month. The relative copy number of both plasmids declined thereafter, such that by 6 months in continuous culture, the B95.8 plasmids were undetectable while approximately 10% of the maximum amount (about two copies per cell) of the CMVRaji.E1 episomes were still present (Figure 5a and b) . The eventual decline in episome copy number over time could reflect gradual inactivation of the CMV promoter by CpG methylation, resulting in decreased EBNA1 expression and eventual loss of the episomes irrespective of the EBNA1 isoform encoded on these plasmids. The CMV promoter used in these experiments has approximately 36 CpG sites. This particular viral promoter has been utilized in many integrative gene delivery systems and has been shown to be rapidly inactivated in vitro and especially in vivo. 29, 30 Alternatively, the relatively abrupt loss of episomal DNA occurring over time could be due to EBNA-1 toxicity, and/or the slow growth of human B cells expressing EBNA-1. Theoretical models can explain the 'sudden' plasmid loss, a phenomenon extensively studied in bacteria. 31 Various factors have been shown to alter the shape of the curve of such a 'sudden loss rate', including cell growth and transgene toxicity. If so, the increased loss of episomes in the presence of the IR3-deleted EBNA-1 could be due to a more pronounced toxic effect of this mutant protein on cell metabolism.
Since the coding region of the EBNA1 truncation mutant was derived from the wild-type B95.8 EBNA1, 24 the differential plasmid stability observed between these two isoforms implies a role for the GlyAla domain. Interestingly, the increased rate of episomal loss in the presence of the GlyAla deletion EBNA-1 mutant was also observed in EBV-positive human B cell HH514 expressing an endogenous EBNA-1 (Figure 4d) . Hence, such a negative trans-dominant interference by the deleted EBNA-1 isoform supports the cooperative role of this protein on OriP activation. Indeed, EBNA-1 binds as a dimer to its cognate sequence and multiple binding on OriP is required for episomal persistence. 11, 13, 23 It is difficult to predict how the GlyAla domain influences EBNA1 activity, since most of the biochemical and structural analyses of the EBNA1 protein were deduced from experiments using GlyAla truncated forms of EBNA1. 32, 33 It has been documented that EBNA1 mediates the interaction between the FR and the DS element of OriP. [15] [16] [17] One possible explanation is that the plasmid segregation function of EBNA1 could be affected through a compromised linkage of the amino terminus to the carboxyl terminus of EBNA1 due to a reduction in the GlyAla domain. The experiments which located the DNA linking domains on EBNA1 were performed using GlyAla deletion mutants, and no comparative analysis of the linking function (or efficiency) of normal versus truncated EBNA1 proteins in long-term plasmid maintenance assays has yet been reported. The presence or not of the GlyAla domain may also affect the affinity or interaction of EBNA1 with an unidentified cellular factor involved in the segregation of DNA during mitosis.
The reasons for the difference in functional kinetics between the two wild-type EBNA1s from Raji and B95.8 are less clear. The partial removal of the GlyAla domain in Raji EBNA1 (approximately 100 amino acids) may stimulate its function in long-term plasmid maintenance. Not only is the GlyAla domain of the EBNA1 protein from Raji approximately 100 amino acids shorter than the B95.8 derivative, it also has 14 amino acid differences in the C-terminus where the DNA binding and dimerization domains are located (Figure 1 ). For comparison, the amino acid differences of the EBNA1 protein derived from an EBV-positive nasopharyngeal carcinoma (NPC) were also included. 34 According to a detailed mutational analysis of the functional domains of the B95.8 EBNA1, most of the amino acid changes in the Raji EBNA1 are in regions important for EBNA1 activity. 21 Of potential importance is the finding of a change in position 471 from a glutamine residue in the B95.8 EBNA1 to a glutamic acid residue in the Raji EBNA1. This residue is located in one of three subdomains within the 28 amino acid region that abolished DNA binding when deleted. 21 Role of EBNA1 threshold on long-term episome persistence and transgene expression Our results also indicate a potential minimum threshold level of EBNA1 protein necessary to establish extrachromosomal maintenance of OriP-based plasmids. The relative amount of the B95.8 EBNA1 protein expressed after 5 months (Figure 4b ) did not correlate with the copy number of episomes in these cells (Figures 4a and 5a) . Specifically, the relative amount of the B95.8 EBNA1 protein shown in Figure 4b (lane 6) was estimated to be approximately one-tenth the Raji EBNA1 protein (lane 7), yet the relative difference in copy number between the two plasmids was less than two-fold (Figures 5b, lanes  14 and 15) . It has been reported that EBV copy number does not correlate with the amount of EBNA1 in the cell nucleus. 35 Sternas et al 35 estimated in EBV-positive B cell lines that the number of EBNA1 molecules per cell ranged between 25 000 and 44 000 (less than two-fold difference), while the number of EBV DNA copies ranged between 10 and 400 (40-fold difference). Conversely, our data show that a large fluctuation in the level of EBNA1 protein does not significantly affect the copy number of episomes (an approximate 10-fold difference in EBNA1 protein, yet only a two-fold plasmid copy number difference). It should be noted, though, that the EBV-positive cells used in the experiments of Sternas et al are qualitatively different than the EBV-negative cells used in our experiments. Once the number of EBNA1 molecules falls below a certain threshold, episomes probably integrate as indicated by the absence of detectable episomes after 4 months for CMVIR3del.E1 and after 6 months for the CMVB95.8.E1 transformants (Figure 5a , lane 17). In support, we observed that expression of the EBNA1 protein from a weak cellular promoter (relative to CMV) was insufficient to establish the same OriP/EBNA1 episomes in DG75 or BL30, another EBVnegative BL cell line (unpublished data). Altogether, these results imply that a threshold level of EBNA1 expression is required in human cells to establish episomal maintenance of transfected OriP-based plasmids.
The experiments presented here indicate that the absence of the GlyAla domain of EBNA1 influences the ability of this protein to function adequately at OriP. This subtle influence becomes evident in long-term plasmid maintenance and transgene expression assays. We observed that a novel EBNA1 isoform isolated from Raji EBV, may be functionally superior to the standard B95.8-derived EBNA1 in plasmid persistence and transgene expression. It was shown that transgenes will be expressed at high levels for prolonged periods provided that OriP/EBNA1 plasmids remain episomal. Several observations were made from the fine comparison of the relative changes in ␤-gal activity (Figure 4c ) and copy number (Figure 5b ) as a function of time. First, both of these endpoints became drastically reduced after longterm cultures reflecting a common inactivating event, irrespective of the plasmid. Second, an accelerated decrease occurred for both parameters with the IR3-deleted vector. Third, the relative levels of ␤-gal activity and episomal copy numbers did not always appear to be directly proportional, particularly at early time-points. The EBNA-1-mediated transcriptional activation of the SV40 promoter driving the ␤-gal expression may respond differentially to variable levels of EBNA-1 protein (Figures 3b and 4b) than replication initiation at OriP. Alternatively, squelching on the SV40 promoter, ie titration of a limiting transcriptional factor, may saturate the level of transgene expression at high episomal copy number. At later time-points, however, both values were decreased by 10-to 100-fold, while being maintained at the highest levels in cells expressing the EBNA-1 Raji (Figures 4c, d and 5b) .
In summary, the main conclusions of this work are: (1) the relative instability of an IR3-deleted EBNA-1; and (2) the enhanced stability of the EBNA-1 Raji for longterm maintenance of OriP-based plasmids in human cells. These findings are relevant to gene delivery protocols designed for persistence of extrachromosomal plasmids. Current OriP/EBNA-1 plasmids require selection because of low transfection efficiencies and relative instability in dividing human cells. Obviously, ex vivo gene therapy protocols which are based on the in vitro selection of stably transduced cells, can use the hygromycin selection. In addition, there are in vivo-selectable genes which could replace the hygromycin as dominant marker drug. 36 The development of episomal gene delivery vectors that can deliver sustained gene expression, without potentially harmful integration, would be advantageous in treating patients with various and common genetic deficiencies via gene therapy.
Materials and methods
Cells and cell culture Epstein-Barr virus (EBV)-positive Raji and HH514 cells 8, 35 and EBV-negative DG75 and BJAB cells (a gift from Dr Shannon Kenney, UNC, Chapel Hill, NC, USA) were grown in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum, glutamine and antibiotics.
Subcloning of Raji EBNA1
Large covalently closed EBV episomes were prepared from Raji as previously described. 8, 37 Approximately 20 g nucleic acid were digested with the restriction enzymes BamHI and HindIII for 2 h at 37°C until completion. Double-digested restriction fragments were shotgun ligated into the plasmid pGEM3zf(+) (Promega, Madison, WI, USA) which had been previously digested with the same enzymes. Ligation products were transformed into competent XL1 blue MRFЈ bacteria and plated on LB agar plates containing ampicillin and X-gal. Approximately 500 white colonies were picked and transferred on to large 150-mm LB-AX plates and screened by colony hybridization using the EBNA1 gene as a probe. Seven colonies were positively identified and their partial EBNA-1 sequence (Miniprep DNA (Flexiprep); Pharmacia, Piscataway, NJ, USA) was shown to be identical. The complete nucleotide sequence of one randomly chosen Raji EBNA1 gene was determined by manual sequencing (Sequenase; US Biochemical, Cleveland, OH, USA).
EBNA1 expression constructs
The plasmids pH210 8 and pH211 (Figure 2 ) with no EBNA-1 contain the following cis-acting elements: (i) the lytic origin of replication of EBV (oriLyt); (ii) packaging signals (terminal repeat, TR); and (iii) the latent origin of plasmid replication and EBNA1 binding sites (oriP). A HindIII restriction fragment containing the CMVEBNA1 (B95.8-derived EBNA1) expression cassette from the commercially available pCMVEBNA1 plasmid (Invitrogen, San Diego, CA, USA) was inserted into the HindIII site of the miniEBV plasmid pH211 to give CMVB958.E1 (Figure 2) . To construct the Raji and the IR3del EBNA1 expression cassettes, the AvrII to SacII restriction fragment of the EBNA1 coding region in pCMVEBNA1 was replaced by or swapped with the analogous restriction fragment from the Raji and IR3del EBNA1s. The IR3del EBNA1 coding region was derived from the plasmid pREP7 from Invitrogen. This clone of EBNA1 has a large deletion in the GlyAla repeat region. The HindIII expression cassette from these subclones was then transferred to the singular HindIII site of plasmid pH211 to give CMVRaji.E1 and CMVIR3del.E1, respectively ( Figure 2 ). All clones were analyzed by restriction analysis to confirm and to determine orientation of inserts.
Transfection of mini-EBV plasmids
Ten micrograms of the plasmid pH211 and EBNA1-expressing derivatives ( Figure 2 ) were electroporated into 1 × 10 7 EBV-negative DG75 cells as previously described. 8, 37 Stable cell pools were selected by growth in the antibiotic hygromycin B at 200 g/ml. The positive control for episomal replication was provided by Raji cells stably transformed with pH210.
8,37
Western blot procedure Approximately 1 × 10 7 cells were harvested, washed in PBS, and resuspended in 300-500 l ELB (250 mm NaCl, 50 mm Hepes, pH 7.0, 5 mm EDTA) containing 1.0 mm phenylmethylsulfonyl fluoride (PMSF), 0.5 mm dithiothreitol (DTT), 0.1% NP-40. Protein concentration was determined using Coomassie Plus reagent. For each experiment 40 g protein was loaded per lane and separated on 7.5% SDS-PAGE. Rainbow molecular weight markers (Amersham, Arlington Heights, IL, USA) were used in each gel. Proteins were transferred to nitrocellulose (Micron Separations, Westbro, MA, USA) in a Semidry Transfer unit (BioRad, Hercules, CA, USA) for 30 min at 20 volts. The membrane was blocked overnight at 4°C in TBST containing 3% nonfat dry milk. The membrane was then incubated for 30 min at room temperature with an EBNA1-specific monoclonal antibody, EBNA1.OT1x (gift from JM Middeldorp and SD Hayward, Johns Hopkins School of Medicine, Baltimore, MA, USA). 21 The secondary antibody was goat anti-mouse IgG. Proteins were detected by ECL (Amersham).
Episome purification procedure and Southern blot analysis The preparation of the episomes for analysis was performed as previously described. Briefly, 1 × 10 7 cells were harvested and washed in PBS. Cells were lysed at pH 12.45 in 2 ml cell lysis buffer with vortexing. Lysates were incubated at 30°C before the step-wise addition of 400 l 1 m TrisCl pH 7.0, 264 l 5 m NaCl, 12 l 10 mg/ml proteinase K. The lysates were then incubated for at least 2 h at 37°C. Samples were organic extracted and ethanol precipitated. The OD at 260 nm was determined to calculate the concentration of total nucleic acid. Equivalent amounts of nucleic acid were (30 or 40 g) digested with BglII restriction enzyme to linearize the plasmid and separated on to 0.8% agarose pulse field gels. Nucleic acids were then transferred to nylon membranes (Micron Separations) in 0.2 n NaOH overnight. Blots were then analyzed with probes synthesized using Primagene (Promega). Signals on the blots were then quantified using a Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA). The human mitochondrial probe was derived from the PCR amplification of a small region within the 5.4-kb HindIII fragment of human mitochondrial DNA (16 kb) . The sequence of the primers that were used are as follows: 5ЈTTCTCCTTACACCTAG CAGG,5ЈTAGCGATGATTAT GGTAGCG. The annealing temperature of the primer combination was 58°C.
Colorimetric ONPG assay (lacZ assay) Approximately 2 × 10 6 cells were harvested and washed in PBS. Cells were resuspended in 0.5 ml PBS and 0.5 ml 2 × ONPG (O-nitrophenyl-␤-d-galactopyranoside) containing 0.1% NP-40 was added and samples were vortexed to lyse the cells. 38 Samples were then incubated for at least 2 h at 37°C. To quantify the amount of lacZ expression from each of the transfected pools, the lysates were diluted at least two-fold and the OD was determined for each sample at 420 nm. Control lacZ expressing cells were Raji cells that had been stably infected with miniEBV pH210. This polyclonal cell line was created by infecting Raji Burkitt's lymphoma cells with pH210 mini-EBV as previously described. 8 
